USANA Health Sciences, Inc. (NYSE:USNA) Insider Sells $178,707.74 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) insider Daniel A. Macuga sold 3,791 shares of USANA Health Sciences stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $47.14, for a total value of $178,707.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

USANA Health Sciences Trading Up 3.4 %

Shares of USNA traded up $1.55 during midday trading on Thursday, hitting $47.10. 105,329 shares of the company’s stock traded hands, compared to its average volume of 81,319. The stock has a market capitalization of $906.20 million, a price-to-earnings ratio of 14.19, a price-to-earnings-growth ratio of 1.27 and a beta of 0.94. USANA Health Sciences, Inc. has a 1 year low of $41.45 and a 1 year high of $69.60. The firm’s fifty day moving average is $46.71 and its 200-day moving average is $48.44.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.52 by $0.35. USANA Health Sciences had a net margin of 6.88% and a return on equity of 12.94%. The firm had revenue of $221.08 million during the quarter, compared to analyst estimates of $206.70 million. On average, equities research analysts anticipate that USANA Health Sciences, Inc. will post 2.73 EPS for the current year.

Hedge Funds Weigh In On USANA Health Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of USNA. SG Americas Securities LLC purchased a new position in shares of USANA Health Sciences during the third quarter worth $581,000. Robeco Institutional Asset Management B.V. grew its position in USANA Health Sciences by 27.0% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 23,819 shares of the company’s stock worth $1,396,000 after purchasing an additional 5,064 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in USANA Health Sciences by 60.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,376 shares of the company’s stock worth $198,000 after purchasing an additional 1,274 shares during the period. Strs Ohio raised its stake in shares of USANA Health Sciences by 4.8% during the 3rd quarter. Strs Ohio now owns 10,900 shares of the company’s stock valued at $638,000 after buying an additional 500 shares during the last quarter. Finally, TD Asset Management Inc lifted its holdings in shares of USANA Health Sciences by 16.2% in the 3rd quarter. TD Asset Management Inc now owns 8,600 shares of the company’s stock valued at $504,000 after buying an additional 1,200 shares during the period. Institutional investors and hedge funds own 54.25% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on USNA. StockNews.com upgraded shares of USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Friday, January 12th. DA Davidson decreased their price objective on shares of USANA Health Sciences from $53.00 to $48.00 and set a “neutral” rating for the company in a research note on Thursday, February 22nd.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.